{"id":365425,"date":"2025-09-01T06:21:23","date_gmt":"2025-09-01T06:21:23","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-contineum-therapeutics\/"},"modified":"2025-09-01T06:21:23","modified_gmt":"2025-09-01T06:21:23","slug":"how-to-buy-contineum-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/","title":{"rendered":"Contineum Therapeutics, Inc. (CTNM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Contineum Therapeutics, Inc. (CTNM) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334027,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-365425","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Contineum Therapeutics, Inc. (CTNM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Contineum Therapeutics, Inc. (CTNM) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Contineum Therapeutics, Inc. (CTNM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Contineum Therapeutics, Inc. (CTNM) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Contineum Therapeutics, Inc. (CTNM) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve CTNM hisselerine yat\u0131r\u0131m yapmay\u0131, mevcut fiyat, riskler ve 2025-2030 b\u00fcy\u00fcme potansiyeli ile ilgili kapsaml\u0131 analizimizle \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Contineum Therapeutics, Inc. (CTNM) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve CTNM hisselerine yat\u0131r\u0131m yapmay\u0131, mevcut fiyat, riskler ve 2025-2030 b\u00fcy\u00fcme potansiyeli ile ilgili kapsaml\u0131 analizimizle \u00f6\u011frenin."},"intro":"\u0130leri teknoloji biyoteknolojiye yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Contineum Therapeutics (CTNM), iki umut vadeden klinik a\u015fama ilac\u0131yla n\u00f6roenflamasyon tedavisinde heyecan verici bir s\u0131n\u0131r\u0131 temsil ediyor. Bu k\u00fc\u00e7\u00fck sermayeli biyoteknoloji \u015firketi patlay\u0131c\u0131 b\u00fcy\u00fcme potansiyeli sunuyor ancak klinik deneme ba\u015far\u0131s\u0131na her \u015feyi yat\u0131ran \u015firketlere \u00f6zg\u00fc volatiliteyi de beraberinde getiriyor. CTNM'nin portf\u00f6y\u00fcn\u00fczde olup olmamas\u0131 gerekti\u011fini ve bu y\u00fcksek riskli, y\u00fcksek \u00f6d\u00fcll\u00fc f\u0131rsata nas\u0131l yakla\u015fman\u0131z gerekti\u011fini ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"\u0130leri teknoloji biyoteknolojiye yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Contineum Therapeutics (CTNM), iki umut vadeden klinik a\u015fama ilac\u0131yla n\u00f6roenflamasyon tedavisinde heyecan verici bir s\u0131n\u0131r\u0131 temsil ediyor. Bu k\u00fc\u00e7\u00fck sermayeli biyoteknoloji \u015firketi patlay\u0131c\u0131 b\u00fcy\u00fcme potansiyeli sunuyor ancak klinik deneme ba\u015far\u0131s\u0131na her \u015feyi yat\u0131ran \u015firketlere \u00f6zg\u00fc volatiliteyi de beraberinde getiriyor. CTNM'nin portf\u00f6y\u00fcn\u00fczde olup olmamas\u0131 gerekti\u011fini ve bu y\u00fcksek riskli, y\u00fcksek \u00f6d\u00fcll\u00fc f\u0131rsata nas\u0131l yakla\u015fman\u0131z gerekti\u011fini ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 CTNM Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2> <p>1 Eyl\u00fcl 2025 itibar\u0131yla Contineum Therapeutics (CTNM), NASDAQ borsas\u0131nda <strong>10,45 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Hisse son zamanlarda b\u00fcy\u00fck bir y\u00fckseli\u015f ya\u015fad\u0131, ancak ger\u00e7ek hareket \u00f6nemli klinik d\u00f6n\u00fcm noktalar\u0131 etraf\u0131nda ger\u00e7ekle\u015fiyor.<\/p> <p><strong>Takviminize not edin: 5 Kas\u0131m 2025<\/strong> kesinlikle kritik bir tarih. Bu tarihte CTNM \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak, ancak daha da \u00f6nemlisi, yat\u0131r\u0131mc\u0131lar Faz II klinik denemeleriyle ilgili her kelimeyi dikkatle takip edecek. Tarihsel olarak, CTNM gibi biyoteknoloji hisseleri sadece klinik g\u00fcncellemelerle %20-50 aras\u0131nda hareket edebilir.<\/p> <h3><strong>Klinik G\u00fcncellemeler CTNM Hissesini Nas\u0131l Hareket Ettirir<\/strong><\/h3> <p>Desen a\u00e7\u0131k: olumlu klinik veriler bu hisseyi u\u00e7ururken, herhangi bir aksilik onu \u00e7\u00f6kertir. A\u011fustos 2025'te, -0,62 $ EPS ile kazan\u00e7 beklentilerini kar\u015f\u0131layamamas\u0131na ra\u011fmen (<a href=\"https:\/\/public.com\/stocks\/ctnm\/earnings\">2. \u00c7eyrek Kazan\u00e7 Raporu<\/a>), hisse asl\u0131nda momentum kazand\u0131 \u00e7\u00fcnk\u00fc yat\u0131r\u0131mc\u0131lar daha b\u00fcy\u00fck resme, yakla\u015fan Faz II veri a\u00e7\u0131klamalar\u0131na odaklanm\u0131\u015ft\u0131.<\/p> <p>En dramatik \u00f6rnek? \u00dc\u00e7 ayl\u0131k performansa bak\u0131n: <strong>%157,8 art\u0131\u015f<\/strong> piyasa genelinin sadece %11 kazand\u0131\u011f\u0131 d\u00f6nemde (<a href=\"https:\/\/marketchameleon.com\/Overview\/CTNM\/Summary\/\">Piyasa Performans Verileri<\/a>). \u0130\u015fte klinik kataliz\u00f6r yat\u0131r\u0131mlar\u0131n\u0131n g\u00fcc\u00fc.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-Eyl\u00fcl 2025)<\/h2> <p>CTNM hisseleri, herhangi bir tema park\u0131n\u0131 k\u0131skand\u0131racak bir h\u0131z treni gibi hareket etti:<\/p> <ul> <li><strong>Mart 2025<\/strong>: Y\u0131ll\u0131k dip seviyeler civar\u0131nda 3,35 $ civar\u0131nda i\u015flem g\u00f6rd\u00fc<\/li> <li><strong>May\u0131s 2025<\/strong>: Klinik deneme kayd\u0131n\u0131n tamamlanmas\u0131yla rallinin ba\u015flang\u0131c\u0131<\/li> <li><strong>Temmuz 2025<\/strong>: Olumlu analist yorumlar\u0131yla 8,00 $ seviyesini a\u015fmas\u0131<\/li> <li><strong>A\u011fustos 2025<\/strong>: Faz II veri beklentilerinin artmas\u0131yla 10,45 $ seviyesine ula\u015fmas\u0131<\/li> <\/ul> <p>Bu inan\u0131lmaz y\u00fckseli\u015fin sebebi? \u0130ki kelime: <strong>klinik kataliz\u00f6rler<\/strong>. \u015eirket, Ocak 2025'te multipl skleroz tedavisi i\u00e7in Faz II VISTA denemesinde kay\u0131tlar\u0131 tamamlad\u0131 (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/CTNM\/fda-events\/\">FDA Deneme G\u00fcncellemeleri<\/a>) ve yat\u0131r\u0131mc\u0131lar olumlu sonu\u00e7lara b\u00fcy\u00fck bahis oynuyor.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <ul> <li><strong>2025 (Y\u0131l Sonu)<\/strong>: 14-16 $ aral\u0131\u011f\u0131 - Bu, PIPE-307 ve PIPE-791 i\u00e7in olumlu Faz II veri a\u00e7\u0131klamalar\u0131n\u0131 varsayar. Her iki deneme de hedeflerine ula\u015f\u0131rsa, analist hedefleri olan 23 $+ seviyelerine do\u011fru patlay\u0131c\u0131 bir hareket g\u00f6rebiliriz.<\/li> <li><strong>2026<\/strong>: 18-22 $ - Olas\u0131 Faz III ba\u015flat\u0131lmas\u0131 ve ortakl\u0131k g\u00f6r\u00fc\u015fmeleri. PIPE-307 i\u00e7in Johnson & Johnson i\u015f birli\u011fi \u00f6nemli kilometre ta\u015flar\u0131 \u00f6demeleri getirebilir.<\/li> <li><strong>2028<\/strong>: 30-40 $ - Bir veya her iki lider aday i\u00e7in FDA onay\u0131 olas\u0131l\u0131\u011f\u0131. \u0130lk ticari gelirlerin elde edilmesi.<\/li> <li><strong>2030<\/strong>: 50 $+ - Multipl skleroz ve pulmoner fibroz pazarlar\u0131nda yerle\u015fik ticari varl\u0131k.<\/li> <\/ul> <p><strong>Karar<\/strong>: <strong>R\u0130SK TOLERANSI Y\u00dcKSEK YATIRIMCILAR \u0130\u00c7\u0130N G\u00dc\u00c7L\u00dc ALIM<\/strong>. Klinik kataliz\u00f6r takvimi potansiyel yukar\u0131 y\u00f6nl\u00fc tetikleyicilerle dolu.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3><strong>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/strong><\/h3> <ul> <li><strong>Klinik ba\u015far\u0131s\u0131zl\u0131k riski<\/strong>: Faz II verileri hayal k\u0131r\u0131kl\u0131\u011f\u0131 yaratabilir - biyoteknoloji ikili sonu\u00e7ludur<\/li> <li><strong>Nakit t\u00fcketimi<\/strong>: 190,7 milyon $ nakit pozisyonu (<a href=\"https:\/\/trial.medpath.com\/news\/3bd649b4253ffb0c\/contineum-therapeutics-on-track-for-key-clinical-milestones-with-pipe-791-and-pipe-307-programs\">Finansal G\u00fcncelleme<\/a>) 2027 sonuna kadar yeterli olmal\u0131<\/li> <li><strong>Hisse seyrelme riski<\/strong>: Karl\u0131l\u0131\u011fa ula\u015fmadan \u00f6nce muhtemelen daha fazla sermaye art\u0131r\u0131m\u0131 gerekecek<\/li> <li><strong>Reg\u00fclasyon belirsizli\u011fi<\/strong>: FDA onay s\u00fcreci asla garanti de\u011fildir<\/li> <\/ul> <h3><strong>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/strong><\/h3> <ul> <li><strong>Faz II veri a\u00e7\u0131klamalar\u0131<\/strong>: Hem PIPE-307 (multipl skleroz) hem de PIPE-791 (pulmoner fibroz) i\u00e7in 2025 ikinci yar\u0131s\u0131nda veri bekleniyor<\/li> <li><strong>Analist heyecan\u0131<\/strong>: <a href=\"https:\/\/www.marketbeat.com\/instant-alerts\/contineum-therapeutics-nasdaqctnm-stock-price-expected-to-rise-morgan-stanley-analyst-says-2025-08-18\/\">Morgan Stanley hedef fiyat\u0131 21 $'a y\u00fckseltti<\/a><\/li> <li><strong>G\u00fc\u00e7l\u00fc nakit pozisyonu<\/strong>: 2027'ye kadar finansman sa\u011flanmas\u0131 k\u0131sa vadeli seyrelme riskini azalt\u0131yor<\/li> <li><strong>Johnson & Johnson ortakl\u0131\u011f\u0131<\/strong>: Do\u011frulama ve potansiyel kilometre ta\u015f\u0131 \u00f6demeleri sa\u011fl\u0131yor<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazlas\u0131n\u0131 CTNM gibi y\u00fcksek riskli biyoteknolojiye ay\u0131rmay\u0131n<\/li> <li><strong>Kas\u0131m ay\u0131n\u0131 bekleyin<\/strong>: 5 Kas\u0131m kazan\u00e7\/g\u00fcncelleme daha iyi giri\u015f noktalar\u0131 sa\u011flayabilir<\/li> <li><strong>Limit emirleri kullan\u0131n<\/strong>: Volatil biyoteknoloji hisselerinde piyasa emri vermeyin - fiyat\u0131n\u0131z\u0131 belirleyin<\/li> <li><strong>Esprili yakla\u015f\u0131m<\/strong>: \"CTNM ile i\u015flem yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir - inan\u0131lmaz heyecan verici ama laboratuvarda beklenmedik patlamalara haz\u0131rl\u0131kl\u0131 olun!\"<\/li> <\/ol> <h2>\u2705 Contineum Therapeutics, Inc. (CTNM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir i\u015flem platformu se\u00e7in<\/td><td>NASDAQ eri\u015fimi ve biyoteknoloji hisseleri sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesab\u0131n\u0131z\u0131 fonlay\u0131n<\/td><td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>CTNM'yi ara\u015ft\u0131r\u0131n<\/td><td>Klinik kataliz\u00f6rleri ve riskleri anlay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Limit emri belirleyin<\/td><td>Volatilite zirvelerinde fazla \u00f6deme yapmaktan ka\u00e7\u0131n\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Klinik takvimi takip edin<\/td><td>5 Kas\u0131m ve gelecekteki veri a\u00e7\u0131klama tarihlerini i\u015faretleyin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Neden Pocket Option CTNM Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2> <p>CTNM gibi volatil biyoteknoloji hisselerinde i\u015flem yapmak esneklik ve d\u00fc\u015f\u00fck giri\u015f engelleri gerektirir. Pocket Option her ikisini de sunar:<\/p> <ul> <li><strong>Minimum depozito sadece 5 $<\/strong> - K\u00fc\u00e7\u00fck pozisyonlarla stratejileri test etmek i\u00e7in m\u00fckemmel<\/li> <li><strong>Y\u0131ld\u0131r\u0131m h\u0131z\u0131nda do\u011frulama<\/strong> - Tek belge KYC ile hemen i\u015flem yapmaya ba\u015flay\u0131n<\/li> <li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> - Kripto para, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil<\/li> <\/ul> <p>\u00d6zellikle CTNM i\u00e7in d\u00fc\u015f\u00fck minimumlar, portf\u00f6y\u00fcn\u00fcz\u00fc biyoteknoloji volatilitesine a\u015f\u0131r\u0131 maruz b\u0131rakmadan pozisyon kurman\u0131z\u0131 sa\u011flar.<\/p> <h2>\ud83c\udf0d 2025'te Contineum: N\u00f6robilim Yenilik\u00e7isi<\/h2> <p>Contineum Therapeutics, a\u011f\u0131rl\u0131k s\u0131n\u0131f\u0131n\u0131n \u00e7ok \u00fczerinde performans g\u00f6steriyor. Bu 279 milyon $ piyasa de\u011ferine sahip \u015firket (<a href=\"https:\/\/marketchameleon.com\/Overview\/CTNM\/Summary\/\">Piyasa De\u011feri Verileri<\/a>), multipl skleroz ve pulmoner fibroz i\u00e7in devrim niteli\u011finde tedaviler geli\u015ftiriyor ve bunlar yeni etki mekanizmalar\u0131yla sa\u011flan\u0131yor.<\/p> <p>\u015eirketin iki lider aday\u0131 tamamen yeni yakla\u015f\u0131mlar sunuyor:<\/p> <ul> <li><strong>PIPE-307<\/strong>: Multipl skleroz i\u00e7in M1 resept\u00f6r antagonisti (J&amp;J ile ortakl\u0131k)<\/li> <li><strong>PIPE-791<\/strong>: Pulmoner fibroz ve kronik a\u011fr\u0131 i\u00e7in LPA1 inhibit\u00f6r\u00fc<\/li> <\/ul> <p><strong>2025 e\u011flenceli bilgi<\/strong>: Contineum'un ara\u015ft\u0131rma yakla\u015f\u0131m\u0131 o kadar yenilik\u00e7i ki, n\u00f6roenflamasyonu bu spesifik yollarla hedefleme konusunda adeta ders kitab\u0131 yaz\u0131yorlar. Ba\u015far\u0131 sadece finansal getiri de\u011fil, ayn\u0131 zamanda bu y\u0131k\u0131c\u0131 hastal\u0131klar\u0131n tedavisinde devrim anlam\u0131na gelebilir.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 CTNM Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2>\n<p>1 Eyl\u00fcl 2025 itibar\u0131yla Contineum Therapeutics (CTNM), NASDAQ borsas\u0131nda <strong>10,45 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Hisse son zamanlarda b\u00fcy\u00fck bir y\u00fckseli\u015f ya\u015fad\u0131, ancak ger\u00e7ek hareket \u00f6nemli klinik d\u00f6n\u00fcm noktalar\u0131 etraf\u0131nda ger\u00e7ekle\u015fiyor.<\/p>\n<p><strong>Takviminize not edin: 5 Kas\u0131m 2025<\/strong> kesinlikle kritik bir tarih. Bu tarihte CTNM \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak, ancak daha da \u00f6nemlisi, yat\u0131r\u0131mc\u0131lar Faz II klinik denemeleriyle ilgili her kelimeyi dikkatle takip edecek. Tarihsel olarak, CTNM gibi biyoteknoloji hisseleri sadece klinik g\u00fcncellemelerle %20-50 aras\u0131nda hareket edebilir.<\/p>\n<h3><strong>Klinik G\u00fcncellemeler CTNM Hissesini Nas\u0131l Hareket Ettirir<\/strong><\/h3>\n<p>Desen a\u00e7\u0131k: olumlu klinik veriler bu hisseyi u\u00e7ururken, herhangi bir aksilik onu \u00e7\u00f6kertir. A\u011fustos 2025&#8217;te, -0,62 $ EPS ile kazan\u00e7 beklentilerini kar\u015f\u0131layamamas\u0131na ra\u011fmen (<a href=\"https:\/\/public.com\/stocks\/ctnm\/earnings\">2. \u00c7eyrek Kazan\u00e7 Raporu<\/a>), hisse asl\u0131nda momentum kazand\u0131 \u00e7\u00fcnk\u00fc yat\u0131r\u0131mc\u0131lar daha b\u00fcy\u00fck resme, yakla\u015fan Faz II veri a\u00e7\u0131klamalar\u0131na odaklanm\u0131\u015ft\u0131.<\/p>\n<p>En dramatik \u00f6rnek? \u00dc\u00e7 ayl\u0131k performansa bak\u0131n: <strong>%157,8 art\u0131\u015f<\/strong> piyasa genelinin sadece %11 kazand\u0131\u011f\u0131 d\u00f6nemde (<a href=\"https:\/\/marketchameleon.com\/Overview\/CTNM\/Summary\/\">Piyasa Performans Verileri<\/a>). \u0130\u015fte klinik kataliz\u00f6r yat\u0131r\u0131mlar\u0131n\u0131n g\u00fcc\u00fc.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-Eyl\u00fcl 2025)<\/h2>\n<p>CTNM hisseleri, herhangi bir tema park\u0131n\u0131 k\u0131skand\u0131racak bir h\u0131z treni gibi hareket etti:<\/p>\n<ul>\n<li><strong>Mart 2025<\/strong>: Y\u0131ll\u0131k dip seviyeler civar\u0131nda 3,35 $ civar\u0131nda i\u015flem g\u00f6rd\u00fc<\/li>\n<li><strong>May\u0131s 2025<\/strong>: Klinik deneme kayd\u0131n\u0131n tamamlanmas\u0131yla rallinin ba\u015flang\u0131c\u0131<\/li>\n<li><strong>Temmuz 2025<\/strong>: Olumlu analist yorumlar\u0131yla 8,00 $ seviyesini a\u015fmas\u0131<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: Faz II veri beklentilerinin artmas\u0131yla 10,45 $ seviyesine ula\u015fmas\u0131<\/li>\n<\/ul>\n<p>Bu inan\u0131lmaz y\u00fckseli\u015fin sebebi? \u0130ki kelime: <strong>klinik kataliz\u00f6rler<\/strong>. \u015eirket, Ocak 2025&#8217;te multipl skleroz tedavisi i\u00e7in Faz II VISTA denemesinde kay\u0131tlar\u0131 tamamlad\u0131 (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/CTNM\/fda-events\/\">FDA Deneme G\u00fcncellemeleri<\/a>) ve yat\u0131r\u0131mc\u0131lar olumlu sonu\u00e7lara b\u00fcy\u00fck bahis oynuyor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<ul>\n<li><strong>2025 (Y\u0131l Sonu)<\/strong>: 14-16 $ aral\u0131\u011f\u0131 &#8211; Bu, PIPE-307 ve PIPE-791 i\u00e7in olumlu Faz II veri a\u00e7\u0131klamalar\u0131n\u0131 varsayar. Her iki deneme de hedeflerine ula\u015f\u0131rsa, analist hedefleri olan 23 $+ seviyelerine do\u011fru patlay\u0131c\u0131 bir hareket g\u00f6rebiliriz.<\/li>\n<li><strong>2026<\/strong>: 18-22 $ &#8211; Olas\u0131 Faz III ba\u015flat\u0131lmas\u0131 ve ortakl\u0131k g\u00f6r\u00fc\u015fmeleri. PIPE-307 i\u00e7in Johnson &#038; Johnson i\u015f birli\u011fi \u00f6nemli kilometre ta\u015flar\u0131 \u00f6demeleri getirebilir.<\/li>\n<li><strong>2028<\/strong>: 30-40 $ &#8211; Bir veya her iki lider aday i\u00e7in FDA onay\u0131 olas\u0131l\u0131\u011f\u0131. \u0130lk ticari gelirlerin elde edilmesi.<\/li>\n<li><strong>2030<\/strong>: 50 $+ &#8211; Multipl skleroz ve pulmoner fibroz pazarlar\u0131nda yerle\u015fik ticari varl\u0131k.<\/li>\n<\/ul>\n<p><strong>Karar<\/strong>: <strong>R\u0130SK TOLERANSI Y\u00dcKSEK YATIRIMCILAR \u0130\u00c7\u0130N G\u00dc\u00c7L\u00dc ALIM<\/strong>. Klinik kataliz\u00f6r takvimi potansiyel yukar\u0131 y\u00f6nl\u00fc tetikleyicilerle dolu.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3><strong>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/strong><\/h3>\n<ul>\n<li><strong>Klinik ba\u015far\u0131s\u0131zl\u0131k riski<\/strong>: Faz II verileri hayal k\u0131r\u0131kl\u0131\u011f\u0131 yaratabilir &#8211; biyoteknoloji ikili sonu\u00e7ludur<\/li>\n<li><strong>Nakit t\u00fcketimi<\/strong>: 190,7 milyon $ nakit pozisyonu (<a href=\"https:\/\/trial.medpath.com\/news\/3bd649b4253ffb0c\/contineum-therapeutics-on-track-for-key-clinical-milestones-with-pipe-791-and-pipe-307-programs\">Finansal G\u00fcncelleme<\/a>) 2027 sonuna kadar yeterli olmal\u0131<\/li>\n<li><strong>Hisse seyrelme riski<\/strong>: Karl\u0131l\u0131\u011fa ula\u015fmadan \u00f6nce muhtemelen daha fazla sermaye art\u0131r\u0131m\u0131 gerekecek<\/li>\n<li><strong>Reg\u00fclasyon belirsizli\u011fi<\/strong>: FDA onay s\u00fcreci asla garanti de\u011fildir<\/li>\n<\/ul>\n<h3><strong>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/strong><\/h3>\n<ul>\n<li><strong>Faz II veri a\u00e7\u0131klamalar\u0131<\/strong>: Hem PIPE-307 (multipl skleroz) hem de PIPE-791 (pulmoner fibroz) i\u00e7in 2025 ikinci yar\u0131s\u0131nda veri bekleniyor<\/li>\n<li><strong>Analist heyecan\u0131<\/strong>: <a href=\"https:\/\/www.marketbeat.com\/instant-alerts\/contineum-therapeutics-nasdaqctnm-stock-price-expected-to-rise-morgan-stanley-analyst-says-2025-08-18\/\">Morgan Stanley hedef fiyat\u0131 21 $&#8217;a y\u00fckseltti<\/a><\/li>\n<li><strong>G\u00fc\u00e7l\u00fc nakit pozisyonu<\/strong>: 2027&#8217;ye kadar finansman sa\u011flanmas\u0131 k\u0131sa vadeli seyrelme riskini azalt\u0131yor<\/li>\n<li><strong>Johnson &#038; Johnson ortakl\u0131\u011f\u0131<\/strong>: Do\u011frulama ve potansiyel kilometre ta\u015f\u0131 \u00f6demeleri sa\u011fl\u0131yor<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3&#8217;\u00fcnden fazlas\u0131n\u0131 CTNM gibi y\u00fcksek riskli biyoteknolojiye ay\u0131rmay\u0131n<\/li>\n<li><strong>Kas\u0131m ay\u0131n\u0131 bekleyin<\/strong>: 5 Kas\u0131m kazan\u00e7\/g\u00fcncelleme daha iyi giri\u015f noktalar\u0131 sa\u011flayabilir<\/li>\n<li><strong>Limit emirleri kullan\u0131n<\/strong>: Volatil biyoteknoloji hisselerinde piyasa emri vermeyin &#8211; fiyat\u0131n\u0131z\u0131 belirleyin<\/li>\n<li><strong>Esprili yakla\u015f\u0131m<\/strong>: &#8220;CTNM ile i\u015flem yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir &#8211; inan\u0131lmaz heyecan verici ama laboratuvarda beklenmedik patlamalara haz\u0131rl\u0131kl\u0131 olun!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 Contineum Therapeutics, Inc. (CTNM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir i\u015flem platformu se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve biyoteknoloji hisseleri sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesab\u0131n\u0131z\u0131 fonlay\u0131n<\/td>\n<td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>CTNM&#8217;yi ara\u015ft\u0131r\u0131n<\/td>\n<td>Klinik kataliz\u00f6rleri ve riskleri anlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Limit emri belirleyin<\/td>\n<td>Volatilite zirvelerinde fazla \u00f6deme yapmaktan ka\u00e7\u0131n\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Klinik takvimi takip edin<\/td>\n<td>5 Kas\u0131m ve gelecekteki veri a\u00e7\u0131klama tarihlerini i\u015faretleyin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option CTNM Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2>\n<p>CTNM gibi volatil biyoteknoloji hisselerinde i\u015flem yapmak esneklik ve d\u00fc\u015f\u00fck giri\u015f engelleri gerektirir. Pocket Option her ikisini de sunar:<\/p>\n<ul>\n<li><strong>Minimum depozito sadece 5 $<\/strong> &#8211; K\u00fc\u00e7\u00fck pozisyonlarla stratejileri test etmek i\u00e7in m\u00fckemmel<\/li>\n<li><strong>Y\u0131ld\u0131r\u0131m h\u0131z\u0131nda do\u011frulama<\/strong> &#8211; Tek belge KYC ile hemen i\u015flem yapmaya ba\u015flay\u0131n<\/li>\n<li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> &#8211; Kripto para, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil<\/li>\n<\/ul>\n<p>\u00d6zellikle CTNM i\u00e7in d\u00fc\u015f\u00fck minimumlar, portf\u00f6y\u00fcn\u00fcz\u00fc biyoteknoloji volatilitesine a\u015f\u0131r\u0131 maruz b\u0131rakmadan pozisyon kurman\u0131z\u0131 sa\u011flar.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Contineum: N\u00f6robilim Yenilik\u00e7isi<\/h2>\n<p>Contineum Therapeutics, a\u011f\u0131rl\u0131k s\u0131n\u0131f\u0131n\u0131n \u00e7ok \u00fczerinde performans g\u00f6steriyor. Bu 279 milyon $ piyasa de\u011ferine sahip \u015firket (<a href=\"https:\/\/marketchameleon.com\/Overview\/CTNM\/Summary\/\">Piyasa De\u011feri Verileri<\/a>), multipl skleroz ve pulmoner fibroz i\u00e7in devrim niteli\u011finde tedaviler geli\u015ftiriyor ve bunlar yeni etki mekanizmalar\u0131yla sa\u011flan\u0131yor.<\/p>\n<p>\u015eirketin iki lider aday\u0131 tamamen yeni yakla\u015f\u0131mlar sunuyor:<\/p>\n<ul>\n<li><strong>PIPE-307<\/strong>: Multipl skleroz i\u00e7in M1 resept\u00f6r antagonisti (J&amp;J ile ortakl\u0131k)<\/li>\n<li><strong>PIPE-791<\/strong>: Pulmoner fibroz ve kronik a\u011fr\u0131 i\u00e7in LPA1 inhibit\u00f6r\u00fc<\/li>\n<\/ul>\n<p><strong>2025 e\u011flenceli bilgi<\/strong>: Contineum&#8217;un ara\u015ft\u0131rma yakla\u015f\u0131m\u0131 o kadar yenilik\u00e7i ki, n\u00f6roenflamasyonu bu spesifik yollarla hedefleme konusunda adeta ders kitab\u0131 yaz\u0131yorlar. Ba\u015far\u0131 sadece finansal getiri de\u011fil, ayn\u0131 zamanda bu y\u0131k\u0131c\u0131 hastal\u0131klar\u0131n tedavisinde devrim anlam\u0131na gelebilir.<\/p>\n"},"faq":[{"question":"Contineum Therapeutics hisseleri nereden al\u0131nabilir?","answer":"Contineum Therapeutics hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir ve bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve i\u015flem platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"CTNM hisseleri ne kadar risklidir?","answer":"CTNM, klinik deneme sonu\u00e7lar\u0131na ba\u011fl\u0131 olarak y\u00fcksek volatiliteye sahip bir biyoteknoloji \u015firketidir. Y\u00fcksek riskli ancak potansiyel olarak y\u00fcksek getirili bir yat\u0131r\u0131md\u0131r."},{"question":"CTNM hisseleri i\u00e7in \u00f6nemli klinik tarihler nelerdir?","answer":"En kritik tarih 5 Kas\u0131m 2025'tir; bu tarihte \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrek kazan\u00e7lar\u0131 ve Faz II klinik deneme sonu\u00e7lar\u0131 a\u00e7\u0131klanacakt\u0131r."},{"question":"CTNM hisseleri i\u00e7in fiyat tahmini nedir?","answer":"2025 sonunda 14-16 $ aral\u0131\u011f\u0131nda, 2030 y\u0131l\u0131nda ise 50 $ ve \u00fczeri seviyelerde i\u015flem g\u00f6rmesi beklenmektedir, ancak bu tahminler klinik sonu\u00e7lara ba\u011fl\u0131d\u0131r."},{"question":"CTNM hisselerine yat\u0131r\u0131m yaparken nelere dikkat etmeliyim?","answer":"Yat\u0131r\u0131m yaparken portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesini ay\u0131rmak, limit emirleri kullanmak ve \u00f6nemli klinik g\u00fcncellemeleri takip etmek \u00f6nemlidir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Contineum Therapeutics hisseleri nereden al\u0131nabilir?","answer":"Contineum Therapeutics hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir ve bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve i\u015flem platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"CTNM hisseleri ne kadar risklidir?","answer":"CTNM, klinik deneme sonu\u00e7lar\u0131na ba\u011fl\u0131 olarak y\u00fcksek volatiliteye sahip bir biyoteknoloji \u015firketidir. Y\u00fcksek riskli ancak potansiyel olarak y\u00fcksek getirili bir yat\u0131r\u0131md\u0131r."},{"question":"CTNM hisseleri i\u00e7in \u00f6nemli klinik tarihler nelerdir?","answer":"En kritik tarih 5 Kas\u0131m 2025'tir; bu tarihte \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrek kazan\u00e7lar\u0131 ve Faz II klinik deneme sonu\u00e7lar\u0131 a\u00e7\u0131klanacakt\u0131r."},{"question":"CTNM hisseleri i\u00e7in fiyat tahmini nedir?","answer":"2025 sonunda 14-16 $ aral\u0131\u011f\u0131nda, 2030 y\u0131l\u0131nda ise 50 $ ve \u00fczeri seviyelerde i\u015flem g\u00f6rmesi beklenmektedir, ancak bu tahminler klinik sonu\u00e7lara ba\u011fl\u0131d\u0131r."},{"question":"CTNM hisselerine yat\u0131r\u0131m yaparken nelere dikkat etmeliyim?","answer":"Yat\u0131r\u0131m yaparken portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesini ay\u0131rmak, limit emirleri kullanmak ve \u00f6nemli klinik g\u00fcncellemeleri takip etmek \u00f6nemlidir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Contineum Therapeutics, Inc. (CTNM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Contineum Therapeutics, Inc. (CTNM) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Contineum Therapeutics, Inc. (CTNM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Contineum Therapeutics, Inc. (CTNM) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-01T06:21:23+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Contineum Therapeutics, Inc. (CTNM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Contineum Therapeutics, Inc. (CTNM) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-09-01T06:21:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/\",\"name\":\"Contineum Therapeutics, Inc. (CTNM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Contineum Therapeutics, Inc. (CTNM) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"datePublished\":\"2025-09-01T06:21:23+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Contineum Therapeutics, Inc. (CTNM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Contineum Therapeutics, Inc. (CTNM) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Contineum Therapeutics, Inc. (CTNM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Contineum Therapeutics, Inc. (CTNM) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Contineum Therapeutics, Inc. (CTNM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Contineum Therapeutics, Inc. (CTNM) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-09-01T06:21:23+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Contineum Therapeutics, Inc. (CTNM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Contineum Therapeutics, Inc. (CTNM) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-09-01T06:21:23+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/","name":"Contineum Therapeutics, Inc. (CTNM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Contineum Therapeutics, Inc. (CTNM) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","datePublished":"2025-09-01T06:21:23+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-contineum-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Contineum Therapeutics, Inc. (CTNM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Contineum Therapeutics, Inc. (CTNM) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":365427,"slug":"how-to-buy-contineum-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Contineum Therapeutics, Inc. (CTNM) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Contineum Therapeutics, Inc. (CTNM)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-contineum-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":365424,"slug":"how-to-buy-contineum-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Contineum Therapeutics, Inc. (CTNM) - Investimento em a\u00e7\u00f5es da Contineum Therapeutics, Inc. (CTNM)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-contineum-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/365425","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=365425"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/365425\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334027"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=365425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=365425"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=365425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}